Mark Metherell
The government's expert panel on prescription drugs is expected to announce tomorrow it is recommending that the drugs telaprevir and boceprevir be listed for prescription subsidies.
The measure, forecast to prevent more than 2200 premature deaths, still depends on a funding green light from the federal government.
The drugs would be used in combination with existing medications that have proved ineffective against the most common and hard-to-treat strain of hepatitis C. That strain has hit more than 100,000 of the 300,000 Australians infected with the disease over the past 25 years.
Continue Reading...
No comments:
Post a Comment